B+
Overall grade
A-
Financial quality
The sleeper story is brepocitinib's steroid taper success proving drug efficacy - 98% compliance and 40% elimination rates suggest the mechanism works, yet Gline admitted he'll 'fight my nails' until seeing placebo data. The obvious headline is imminent DM readout, but the binding constraint is actually management's defensive positioning despite claiming first-mover advantage in a 40K+ patient market with high unmet need. Most revealing quote: 'Really good progress getting patients off steroids gives brepocitinib a truly fair shot' - this isn't trial design, it's efficacy validation. My view changes if the steroid elimination cohort doesn't show superior TIS improvement - that would suggest the drug effect is weaker than the withdrawal benefit.
The 30-second version
- THE SLEEPER STORY: Brepocitinib steroid taper data reveals efficacy mechanism working - 98% hit mandatory taper, 40% eliminated steroids entirely
- DM readout imminent with 'last patient last visit completed' in July - but management unusually nervous for a supposedly differentiated oral-first therapy
- LNP litigation entering summary judgment phase with $1B+ potential upside that nobody's modeling
What changed this quarter
| Metric | Prior | This quarter |
|---|---|---|
| Cash and equivalents | $4.95B (Q4 2024) | $4.5B (Q1 2025) |
| Adjusted net loss | Not disclosed | $170M |
| Cash utilization (ex-buybacks) | $150-160M (Q4) | $200M |
| Share repurchases completed | $1.3B through Q4 | $1.5B program completed |
| VALOR steroid taper success | Not disclosed | 98% achieved mandatory taper |
| VALOR steroid elimination | Not disclosed | 40% eliminated oral steroids |
| Brepocitinib safety database | Over 1,500 patients | Over 1,500 patients |
| 1402 registrational trials | 5 ongoing | 5 ongoing plus Graves enrollment pickup |
Accountability tracked
7 new promises made4 narrative shifts flagged6 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →